Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Dapagliflozin for treating chronic heart failure with reduced ejection fraction

Dapagliflozin for treating chronic heart failure with reduced ejection fraction Dapagliflozin for treating chronic heart failure with reduced ejection fraction T echnology appraisal guidance Published: 24 February 2021 www.nice.org.uk/guidance/ta679 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679) © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 Information about dapagliflozin 6

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

2. A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT Full Text available with Trip Pro

A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could (...) not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This programme found adding the intervention to usual care for people with heart failure with reduced ejection fraction improved quality of life at 12 months compared with usual care alone. {{author}} {{($index , , , , , , , , , , , , , , , , , , , & . Hasnain M Dalal 1, 2, * , Rod S

2021 NIHR HTA programme

3. Vericiguat (Verquvo) - To treat chronic heart failure

Vericiguat (Verquvo) - To treat chronic heart failure Drug Approval Package: VERQUVO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: VERQUVO Company: Merck Sharp & Dohme Corp. Application Number: 214377 Approval Date: 9/19/2021 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

4. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure

Cite Display options Display options Format Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2021 Mar 2;77(8):1029-1040. doi: 10.1016/j.jacc.2020.12.047. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Baylor Scott & White Heart Hospital Plano, Plano, Texas, USA. Electronic address: michael.mack@bswhealth.org. 2 Advanced Heart Failure and Cardiac Transplantation Section (...) Hospital Plano, Plano, Texas, USA. Electronic address: michael.mack@bswhealth.org. 2 Advanced Heart Failure and Cardiac Transplantation Section, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, USA. 3 Departments of Medicine, Physiology, and Cell Biology, Division of Cardiovascular Medicine, and the Davis Heart & Lung Research Institute, The Ohio State University, Columbus, Ohio, USA. 4 Los Robles Regional Medical Center, Thousand Oaks, California, USA; Bakersfield Heart Hospital

2021 EvidenceUpdates

5. 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures

for Heart Failure With Reduced Ejection Fraction in Those Self-Identified as Black or African American (Outpatient and Inpatient Setting) 942 Short Title: PM-12: Counseling Regarding Implantable Cardioverter-Defibrillator Implantation for Patients With Heart Failure With Reduced Ejection Fraction on Guideline-Directed Medical Therapy (Outpatient Setting) 943 Short Title: PM-13: Cardiac Resynchronization Therapy Implantation for Patients With Heart Failure With Reduced Ejection Fraction on Guideline (...) and healthcare organizations for quality improvement. A new safety measure (laboratory monitoring for patients treated with mineralocorticoid receptor antagonists) is paired with a new treatment measure (mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction). Other additions to the performance measures include the new medication sacubitril/valsartan and use of cardiac resynchronization therapy. To address frequent lack of titration of heart

2021 International Society for Heart and Lung Transplantation

6. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF Full Text available with Trip Pro

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Feb;44(2):586-594. doi: 10.2337/dc20-1675. Epub 2020 Dec 18. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection

2021 EvidenceUpdates

7. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial Full Text available with Trip Pro

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Eur Heart J Actions . 2021 Jan 9;ehaa1007. doi: 10.1093/eurheartj/ehaa1007. Online ahead of print. Empagliflozin and health-related quality of life outcomes in patients with heart failure

2021 EvidenceUpdates

8. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo (...) Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2021 Feb;9(2):106-116. doi: 10.1016/S2213-8587(20)30382-X. Epub 2020 Dec 22. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Cardiology

2021 EvidenceUpdates

9. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial Full Text available with Trip Pro

has received steering committee or advisory board fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cardior, CVRx, Janssen, Livanova, Merck, Mundipharma, Novartis, Novo Nordisk, and Vifor Fresenius; and personal fees from Boehringer Ingelheim during the conduct of the study. Figures Figure 1. Total (first and recurrent) adjudicated… Figure 1. Total (first and recurrent) adjudicated heart failure hospitalizations requiring admission to cardiac care… Figure 1. Total (...) (first and recurrent) adjudicated heart failure hospitalizations requiring admission to cardiac care unit or intensive care unit in in the placebo and empagliflozin groups. Shown are mean cumulative function curves for placebo (shown in red) and for empagliflozin (shown in blue). HR indicates hazard ratio. Figure 2. Total (first and recurrent) adjudicated… Figure 2. Total (first and recurrent) adjudicated hospitalization for heart failure requiring intravenous vasopressor or… Figure 2. Total (first

2021 EvidenceUpdates

10. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Full Text available with Trip Pro

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circulation Actions . 2021 Jan 26;143(4):310-321. doi: 10.1161/CIRCULATIONAHA.120.051685. Epub 2020 Oct 23. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From

2021 EvidenceUpdates

11. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF Full Text available with Trip Pro

Cerebral and Cardiovascular Center, Osaka, Japan (M.K.). 10 Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.). 11 Department of Cardiology, Montreal Heart Institute, Canada (E.O.). 12 Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M. Shou). 13 Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia (S.T.). 14 Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Canada (...) Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia (S.T.). 14 Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Canada (S.V.). 15 Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam (P.N.V.). 16 Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.). 17 Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.). 18 Saint Luke's Mid America Heart

2021 EvidenceUpdates

12. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial Full Text available with Trip Pro

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) , University of Heidelberg, Germany (M.B.). 10 Klinik für Innere Medizin III, Saarland University, Homburg/Saar, Germany (M.B.). 11 Heart Institute of the University of Sao Paulo (InCor), Brazil (E.A.B.). 12 Wroclaw Medical University, Poland (P.P.). 13 Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Florencio Varela, Buenos Aires, Argentina (S.V.P.). 14 Harvard Medical School, Massachusetts General Hospital, Boston (J.L.J.). 15 Division of Cardiac Surgery, St Michael's Hospital, University

2021 EvidenceUpdates

13. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial Full Text available with Trip Pro

, and greater use of cardiac devices (all P < 0.001) when compared with those not receiving sacubitril/valsartan. Nevertheless, when compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure in patients receiving or not receiving sacubitril/valsartan [hazard ratio 0.64 (95% CI 0.45-0.89), P = 0.009 and hazard ratio 0.77 (95% CI 0.66-0.90), P = 0.0008, respectively, interaction P = 0.31]. Empagliflozin slowed the rate of decline in estimated glomerular (...) Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search

2021 EvidenceUpdates

14. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Hospital/Östra Hospital, Gothenburg University, Blå stråket 5, 413 45 Gothenburg,Sweden. 12 Department of Cardiology, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, 0372 Oslo,Norway. 13 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Søsterhjemmet, Kirkeveien 166, 2.etasje, 0450 Oslo,Norway. 14 KG Jebsen Center for Cardiac Research, University of Oslo, Sogn Arena, Klaus Torgårds vei 3, 2. Etg, 0372 Oslo,Norway. 15 Center for Heart Failure Research, Department (...) Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced

2021 EvidenceUpdates

15. What is the role of iron supplementation in heart failure

What is the role of iron supplementation in heart failure What is the Role of Iron Supplementation in Heart Failure – Clinical Correlations Search What is the Role of Iron Supplementation in Heart Failure January 8, 2021 4 min read By Varun Subashchandran Peer Reviewed Heart failure is a common health condition that is associated with significant morbidity and mortality. The American Heart Association . 1 In an international pooled analysis of 1506 patients with chronic heart failure, iron (...) deficiency was identified in 50% of patients. 2 This is of concern, as disorders of iron hemostasis lead . 3 In an observational study of 157 patients with congestive heart failure, iron-deficient patients were observed to have decreased exercise tolerance and a 3-fold increased risk of mortality, regardless of anemia status. 3 This is likely due to iron being a required component of metalloproteins involved in oxygen storage and oxidative phosphorylation. 4,5 Iron deficiency leads to biochemical

2021 Clinical Correlations

16. Optimization of Heart Failure Treatment

Optimization of Heart Failure Treatment 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee | Journal of the American College of Cardiology Search Quick Search anywhere Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search (...) Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search Quick Search in Journals Enter Search Terms Search › › › 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection

2021 American College of Cardiology

17. External validation of the ACUTE HF score in patients hospitalized for acute decompensated heart failure

External validation of the ACUTE HF score in patients hospitalized for acute decompensated heart failure External validation of the ACUTE HF score in patients hospitalized for acute decompensated heart failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) validation of the ACUTE HF score in patients hospitalized for acute decompensated heart failure , , , , , Affiliations Expand Affiliations 1 Mugla Sıtkı Kocman University, Training and Research Hospital, Department of Emergency Medicine, Turkey. Electronic address: kmlgokcek@hotmail.com. 2 Mugla Sıtkı Kocman University, Training and Research Hospital, Department of Cardiology, Turkey. 3 Mugla Sıtkı Kocman University, Faculty of Medicine, Department of Emergency Medicine, Turkey. 4 Mugla Sıtkı Kocman

2021 EvidenceUpdates

18. Inspiratory Muscle Training in Patients With Heart Failure: What Is New? Systematic Review and Meta-Analysis

Inspiratory Muscle Training in Patients With Heart Failure: What Is New? Systematic Review and Meta-Analysis Inspiratory Muscle Training in Patients With Heart Failure: What Is New? Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) in Patients With Heart Failure: What Is New? Systematic Review and Meta-Analysis , , Affiliations Expand Affiliations 1 Postgraduate Program in Pneumological Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; and Postgraduate Program in Human Movement Sciences, Universidade Federal do Rio Grande do Sul. 2 Postgraduate Program in Pneumological Sciences, Universidade Federal do Rio Grande do Sul. 3 Postgraduate Program in Pneumological Sciences, Universidade Federal do Rio Grande do

2021 EvidenceUpdates

19. Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial Full Text available with Trip Pro

identifier: . Keywords: heart failure; myocardial ischemia; percutaneous coronary intervention; ventricular dysfunction, left. Similar articles ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, Williams DO, Harrington RA, Rosenberg Y. ISCHEMIA Trial Research Group, et al. Am Heart J. 2018 Jul;201:124-135. doi: 10.1016/j.ahj.2018.04.011. Epub 2018 Apr 21. Am Heart J. 2018 (...) Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features

2020 EvidenceUpdates

20. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial Full Text available with Trip Pro

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) Circulation Actions . 2020 Nov 3;142(18):1713-1724. doi: 10.1161/CIRCULATIONAHA.120.048739. Epub 2020 Aug 29. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial # , # , , , , Affiliations Expand Affiliations 1 Division of Molecular and Clinical Medicine, University of Dundee, Scotland, United Kingdom (N.A.M., I.R.M., R.J.M., A.D.S., C.C.L.). 2 Royal Infirmary of Edinburgh, Scotland, United

2020 EvidenceUpdates